TABLE 2.
Baseline characteristics of study population in different groups stratified by myosteatosis.
| Total |
Myosteatosis |
P | ||
| (N = 473) | No (N = 390) | Yes (N = 83) | ||
| Age (years) | 63(55,69) | 61(53,68) | 69(63,78) | <0.001 |
| Sex, n (%) | 0.277 | |||
| Male | 235 (49.68) | 189 (48.46) | 46 (55.42) | |
| Female | 238 (50.32) | 201 (51.54) | 37 (44.58) | |
| CTP, n (%) | 0.038 | |||
| A | 131 (27.69) | 115 (29.49) | 16 (19.28) | |
| B | 288 (60.89) | 236 (60.51) | 52 (62.65) | |
| C | 54 (11.42) | 39 (10) | 15 (18.07) | |
| MELD score | 10(8,13) | 10(8,13) | 10(8,13) | 0.701 |
| Etiology, n (%) | 0.436 | |||
| HBV/HCV | 137 (28.96) | 117 (30) | 20 (24.10) | |
| Alcohol | 100 (21.14) | 85 (21.79) | 15 (18.07) | |
| MAFLD/AILD | 129 (27.27) | 104 (26.67) | 25 (30.12) | |
| Cryptogenic/Others | 107 (22.63) | 84 (21.54) | 23 (27.71) | |
| Complications, n (%) | ||||
| Ascites | 204 (43.13) | 165 (42.31) | 39 (46.99) | 0.465 |
| Hepatic encephalopathy | 54 (11.42) | 41 (10.51) | 13 (15.66) | 0.185 |
| Gastroesophageal varices | 305 (64.48) | 262 (67.18) | 43 (51.81) | 0.011 |
| Infection | 65 (13.74) | 53 (13.59) | 12 (14.46) | 0.861 |
| DM | 0.152 | |||
| No | 391 (82.66) | 327 (83.85) | 64 (77.11) | |
| Yes | 82 (17.34) | 63 (16.15) | 19 (22.89) | |
| LOH (days) | 13(10,17) | 13(10,17) | 13(9,16) | 0.612 |
| Platelet (*109/L) | 76(54,113.50) | 76(54,114.30) | 76(54,112) | 0.830 |
| Sodium (mmol/L) | 140(137,142) | 140(137,142.50) | 140(137,142) | 0.472 |
| Albumin (g/L) | 30(26,34) | 30(26,34) | 29(25,32) | 0.070 |
| Total bilirubin (μmol/L) | 21.60(14.70,37) | 21.30(14.45,37) | 23.10(16.80,37.40) | 0.358 |
| ALT (U/L) | 21(15,36) | 21(14,36) | 23(16,34) | 0.458 |
| AST (U/L) | 31(23,51) | 30(22,49.75) | 35(26,55) | 0.114 |
| Creatinine (μmol/L) | 61(51,77) | 61(51,77) | 62(50,80) | 0.809 |
| PT-INR | 1.26(1.13,1.41) | 1.26(1.14,1.41) | 1.25(1.12,1.42) | 0.663 |
| NLR | 3.13(1.92,5.49) | 3.09(1.85,5.59) | 3.25(2.08,5.36) | 0.512 |
| PLR | 98.13(67.82,152.50) | 97.87(64.99,151.50) | 102.90(72.64,169.70) | 0.567 |
| LMR | 2.32(1.47,3.29) | 2.38(1.51,3.37) | 1.97(1.37,3.17) | 0.123 |
| Body composition parameters | ||||
| BMI (kg/m2) | 23.76 ± 4.11 | 23.31(20.81,26.04) | 24.74(20.88,27.36) | 0.062 |
| SMI (cm2/m2) | 44.23(37.42,51.29) | 44.03(37.44,51.35) | 44.91(37.33,51.20) | 0.892 |
| Sarcopenia | 130 (27.48) | 101 (25.90) | 29 (34.94) | 0.105 |
| VSR | 1.06(0.76,1.46) | 0.99(0.71,1.39) | 1.30(1.00,1.81) | <0.001 |
| Abnormal adiposity | 129 (27.27) | 95 (24.36) | 34 (40.96) | 0.003 |
| VATI (cm2/m2) | 46.48(29.21,65.05) | 41.62(25.75,61.81) | 59.74(46.69,86.22) | <0.001 |
| High visceral adiposity | 301 (63.64) | 230 (58.97) | 71 (85.54) | <0.001 |
| SATI (cm2/m2) | 40.43(28.8,58.8) | 38.38(28.76,57.73) | 44.43(28.72,65.97) | 0.074 |
| Low subcutaneous adiposity | 112 (23.68) | 94 (24.10) | 18 (21.69) | 0.776 |
| TATI (cm2/m2) | 89.81(59.98,123.40) | 85.75(56.96,117.60) | 109(78.38,154.60) | <0.001 |
| High total adiposity | 262 (55.39) | 202 (51.79) | 60 (72.29) | <0.001 |
CTP, Child-Turcotte-Pugh classification; MELD, model for end-stage liver disease; MAFLD, metabolic dysfunction-associated fatty liver disease; AILD, autoimmune liver disease; DM, diabetes mellitus; LOH, length of hospitalization; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT-INR, prothrombin-international normalized ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; BMI, body mass index; SMI, skeletal muscle index; VSR, visceral to subcutaneous ratio; VATI, visceral adipose tissue index; SATI, subcutaneous adipose tissue index; TATI, total adipose tissue index.